25th Feb 2026 Plain language summary: DESTINY-Lung02 study of trastuzumab deruxtecan for HER2-mutant metastatic non-small-cell lung cancer
22nd Jan 2026 DESTINY-Gastric02 findings on trastuzumab deruxtecan in HER2-positive gastric cancer: plain language summary
20th Dec 2021 Plain language summary of INSIGHT 2: a study to learn about the effects and safety of tepotinib plus osimertinib in patents with a type of non-small cell lung cancer
